Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity

A. Bonomi, V. Coccè, L. Cavicchini, F. Sisto, M. Dossena, P. Balzarini, N. Portolani, E. Ciusani, E. Parati, G. Alessandri, A. Pessina

Research output: Contribution to journalArticle

Abstract

Many strategies, including those based on genetically modified Mesenchymal Stromal Cells (MSCs), have been developed in recent years in order to obtain high concentrations of anticancer drugs effective on tumor mass. In previous studies, we showed that human and murine bone marrow-derived MSCs (BM-MSCs) and human skin-derived stromal fibroblasts (hSDFs) acquired strong anti-tumor capacity, both in vitro and in vivo, once primed with Paclitaxel (PTX). In this report we investigate whether adipose tissue-derived MSCs (AT-MSCs) behave similarly to BM-MSCs in their uptake and release of PTX in sufficient amounts to inhibit tumor proliferation in vitro. According to a standardized procedure, PTX primed AT-MSCs (AT-MSCsPTX) were washed and then subcultured to harvest their conditioned medium, which was then tested to evaluate its in vitro anti-tumor potential. We observed that AT-MSCsPTX were able to uptake PTX and release it in a time-dependent manner and that the released drug was active in vitro against proliferation of leukemia, anaplastic osteosarcoma, prostatic carcinoma and neuroblastoma cell lines. These data confirm that AT-MSCs, as well as BM-MSCs, can be loaded in vitro with anti-cancer drugs. While the harvesting of BM-MSCs requires invasive procedures, AT-MSCs can be prepared from fat samples taken with little patient discomfort. For this reason, this source of stromal cells represents an important alternative to BM-MSCs in developing new tools for carrying and delivering anti-cancer drugs into tumor microenvironments.

Original languageEnglish
Pages (from-to)33-41
Number of pages9
JournalInternational Journal of Immunopathology and Pharmacology
Volume26
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Stromal Cells
Paclitaxel
Adipose Tissue
Bone Marrow
Mesenchymal Stromal Cells
Neoplasms
Pharmaceutical Preparations
Tumor Microenvironment
Osteosarcoma
Conditioned Culture Medium
Neuroblastoma
In Vitro Techniques
Leukemia
Fibroblasts
Fats
Carcinoma
Cell Line
Skin

Keywords

  • drug uptake
  • fat derived MSCs
  • Mesenchymal Stromal Cells
  • Taxol

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity. / Bonomi, A.; Coccè, V.; Cavicchini, L.; Sisto, F.; Dossena, M.; Balzarini, P.; Portolani, N.; Ciusani, E.; Parati, E.; Alessandri, G.; Pessina, A.

In: International Journal of Immunopathology and Pharmacology, Vol. 26, 01.01.2013, p. 33-41.

Research output: Contribution to journalArticle

Bonomi, A. ; Coccè, V. ; Cavicchini, L. ; Sisto, F. ; Dossena, M. ; Balzarini, P. ; Portolani, N. ; Ciusani, E. ; Parati, E. ; Alessandri, G. ; Pessina, A. / Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity. In: International Journal of Immunopathology and Pharmacology. 2013 ; Vol. 26. pp. 33-41.
@article{3736cabf817d48eaaa7e24a6c2dabc21,
title = "Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity",
abstract = "Many strategies, including those based on genetically modified Mesenchymal Stromal Cells (MSCs), have been developed in recent years in order to obtain high concentrations of anticancer drugs effective on tumor mass. In previous studies, we showed that human and murine bone marrow-derived MSCs (BM-MSCs) and human skin-derived stromal fibroblasts (hSDFs) acquired strong anti-tumor capacity, both in vitro and in vivo, once primed with Paclitaxel (PTX). In this report we investigate whether adipose tissue-derived MSCs (AT-MSCs) behave similarly to BM-MSCs in their uptake and release of PTX in sufficient amounts to inhibit tumor proliferation in vitro. According to a standardized procedure, PTX primed AT-MSCs (AT-MSCsPTX) were washed and then subcultured to harvest their conditioned medium, which was then tested to evaluate its in vitro anti-tumor potential. We observed that AT-MSCsPTX were able to uptake PTX and release it in a time-dependent manner and that the released drug was active in vitro against proliferation of leukemia, anaplastic osteosarcoma, prostatic carcinoma and neuroblastoma cell lines. These data confirm that AT-MSCs, as well as BM-MSCs, can be loaded in vitro with anti-cancer drugs. While the harvesting of BM-MSCs requires invasive procedures, AT-MSCs can be prepared from fat samples taken with little patient discomfort. For this reason, this source of stromal cells represents an important alternative to BM-MSCs in developing new tools for carrying and delivering anti-cancer drugs into tumor microenvironments.",
keywords = "drug uptake, fat derived MSCs, Mesenchymal Stromal Cells, Taxol",
author = "A. Bonomi and V. Cocc{\`e} and L. Cavicchini and F. Sisto and M. Dossena and P. Balzarini and N. Portolani and E. Ciusani and E. Parati and G. Alessandri and A. Pessina",
year = "2013",
month = "1",
day = "1",
doi = "10.1177/03946320130260S105",
language = "English",
volume = "26",
pages = "33--41",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",

}

TY - JOUR

T1 - Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity

AU - Bonomi, A.

AU - Coccè, V.

AU - Cavicchini, L.

AU - Sisto, F.

AU - Dossena, M.

AU - Balzarini, P.

AU - Portolani, N.

AU - Ciusani, E.

AU - Parati, E.

AU - Alessandri, G.

AU - Pessina, A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Many strategies, including those based on genetically modified Mesenchymal Stromal Cells (MSCs), have been developed in recent years in order to obtain high concentrations of anticancer drugs effective on tumor mass. In previous studies, we showed that human and murine bone marrow-derived MSCs (BM-MSCs) and human skin-derived stromal fibroblasts (hSDFs) acquired strong anti-tumor capacity, both in vitro and in vivo, once primed with Paclitaxel (PTX). In this report we investigate whether adipose tissue-derived MSCs (AT-MSCs) behave similarly to BM-MSCs in their uptake and release of PTX in sufficient amounts to inhibit tumor proliferation in vitro. According to a standardized procedure, PTX primed AT-MSCs (AT-MSCsPTX) were washed and then subcultured to harvest their conditioned medium, which was then tested to evaluate its in vitro anti-tumor potential. We observed that AT-MSCsPTX were able to uptake PTX and release it in a time-dependent manner and that the released drug was active in vitro against proliferation of leukemia, anaplastic osteosarcoma, prostatic carcinoma and neuroblastoma cell lines. These data confirm that AT-MSCs, as well as BM-MSCs, can be loaded in vitro with anti-cancer drugs. While the harvesting of BM-MSCs requires invasive procedures, AT-MSCs can be prepared from fat samples taken with little patient discomfort. For this reason, this source of stromal cells represents an important alternative to BM-MSCs in developing new tools for carrying and delivering anti-cancer drugs into tumor microenvironments.

AB - Many strategies, including those based on genetically modified Mesenchymal Stromal Cells (MSCs), have been developed in recent years in order to obtain high concentrations of anticancer drugs effective on tumor mass. In previous studies, we showed that human and murine bone marrow-derived MSCs (BM-MSCs) and human skin-derived stromal fibroblasts (hSDFs) acquired strong anti-tumor capacity, both in vitro and in vivo, once primed with Paclitaxel (PTX). In this report we investigate whether adipose tissue-derived MSCs (AT-MSCs) behave similarly to BM-MSCs in their uptake and release of PTX in sufficient amounts to inhibit tumor proliferation in vitro. According to a standardized procedure, PTX primed AT-MSCs (AT-MSCsPTX) were washed and then subcultured to harvest their conditioned medium, which was then tested to evaluate its in vitro anti-tumor potential. We observed that AT-MSCsPTX were able to uptake PTX and release it in a time-dependent manner and that the released drug was active in vitro against proliferation of leukemia, anaplastic osteosarcoma, prostatic carcinoma and neuroblastoma cell lines. These data confirm that AT-MSCs, as well as BM-MSCs, can be loaded in vitro with anti-cancer drugs. While the harvesting of BM-MSCs requires invasive procedures, AT-MSCs can be prepared from fat samples taken with little patient discomfort. For this reason, this source of stromal cells represents an important alternative to BM-MSCs in developing new tools for carrying and delivering anti-cancer drugs into tumor microenvironments.

KW - drug uptake

KW - fat derived MSCs

KW - Mesenchymal Stromal Cells

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=84886731750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886731750&partnerID=8YFLogxK

U2 - 10.1177/03946320130260S105

DO - 10.1177/03946320130260S105

M3 - Article

C2 - 24046947

AN - SCOPUS:84886731750

VL - 26

SP - 33

EP - 41

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

ER -